Dalpiciclib plus HDAC inhibitor for advanced breast cancer after CDK4/6 inhibitor
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs (dalpiciclib and an HDAC inhibitor) for people with hormone receptor-positive, HER2-negative advanced breast cancer that has progressed after a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (recurrent or metastatic) breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER2-negative.
- Your cancer has grown or spread while you were taking a CDK4/6 inhibitor (like palbociclib, abemaciclib, or ribociclib) or after that treatment stopped working.
- You have had no more than one line of chemotherapy for your advanced breast cancer.
- You have not already been treated with an HDAC inhibitor (like vorinostat or romidepsin) or with dalpiciclib.
- You have at least one measurable tumor that is not in the brain, and you do not have active brain metastases or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
This trial tests a combination of three drugs for breast cancer that has spread and has low levels of hormone receptors. The goal is to see if this treatment can help control the cancer.
This trial tests a new targeted therapy pill (dalpiciclib) combined with hormone therapy for women with advanced breast cancer that is hormone-receptor positive and HER2-negative. It may help shrink tumors or slow their growth when chemotherapy is not an option.
This trial tests a combination of two drugs (dalpiciclib and toremifene) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It may be an option if you have not had hormone therapy for advanced disease or if your cancer came back more than a year after prior treatments.
This trial tests a new combination of two drugs (HRS-8080 and Dalpiciclib) for women with advanced breast cancer that cannot be removed by surgery. It may be an option if you have already tried hormone therapy or are starting advanced treatment for the first time.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.